NCT03509831View on ClinicalTrials.gov

[KJ-INT-002] BE Study

PHASE1UnknownINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

January 24, 2018

Study Completion Date

April 30, 2018

Conditions
Gastritis
Interventions
DRUG

INT-2150

"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"

DRUG

Irsogladine maleate 2 mg+Nizatidine 150 mg

"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"

Trial Locations (1)

Unknown

Kukje Pharm, Seongnam-si

Sponsors

Lead Sponsor

Kukje Pharma
All Listed Sponsors
lead

Kukje Pharma

OTHER